Table 5 Drugs of partial substitution
No. | Round | Generic Name | Brand | DDDc | DDDs | ||||
|---|---|---|---|---|---|---|---|---|---|
Before | After | Growth Rate | Before | After | Growth Rate | ||||
27/32, 84.37% (bid-winning brands not used before NCDP and came into use after NCDP) | |||||||||
 1 | First | Montmorillonite powder | Bid-non-winning | 2.20 | 2.20 | 0.00%*** | 6.34 | 6.30 | -0.58% |
Bid-winning | / | 0.83 | / | / | 7.60 | / | |||
 2 | First | Losartan potassium tablets | Bid-non-winning | 5.35 | 4.54 | -15.15%*** | 16.50 | 19.04 | 15.42% |
Bid-winning | / | 1.02 | / | / | 38.17 | / | |||
 3 | First | Clopidogrel bisulfate tablets | Bid-non-winning | 13.49 | 4.30 | -68.10%*** | 14.88 | 17.38 | 16.80% *** |
Bid-winning | / | 3.09 | / | / | 21.13 | / | |||
 4 | First | Irbesartan and hydrochlorothiazide tablets | Bid-non-winning | 2.55 | 2.55 | 0.00%*** | 27.55 | 29.96 | 8.77% |
Bid-winning | / | 1.02 | / | / | 48.55 | / | |||
 5 | First | Irbesartan tablets | Bid-non-winning | 1.43 | 3.06 | 114.11% *** | 24.83 | 16.74 | -32.59% *** |
Bid-winning | / | 0.39 | / | / | 16.33 | / | |||
 6 | First | Amlodipine besilate tablets | Bid-non-winning | 6.34 | 5.19 | -18.10% *** | 15.09 | 12.75 | -15.53% *** |
Bid-winning | / | 0.09 | / | / | 21.84 | / | |||
 7 | First | Amlodipine besylate and atorvastatin calcium tablets | Bid-non-winning | 15.20 | 14.00 | -7.91% | 9.11 | 8.90 | -2.38% *** |
Bid-winning | / | 1.23 | / | / | 11.88 | / | |||
 8 | Second | Bisoprolol fumarate tablets | Bid-non-winning | 2.22 | 2.02 | -8.90% *** | 28.07 | 21.6 | -23.05% |
Bid-winning | / | 0.58 | / | / | 40.55 | / | |||
 9 | Third | Tamsulosin hydrochloride sustained-release capsules | Bid-non-winning | 5.27 | 3.83 | -27.29% *** | 24.56 | 16.16 | -34.20% *** |
Bid-winning | / | 0.50 | / | / | 35.25 | / | |||
 10 | Third | Trimetazidine hydrochloride tablets | Bid-non-winning | 4.23 | 4.19 | -1.01% *** | 22.22 | 15.15 | -31.83% |
Bid-winning | / | 0.24 | / | / | 19.93 | / | |||
 11 | Third | Moxifloxacin hydrochloride and sodium chloride injection | Bid-non-winning | 216.59 | 32.80 | -84.86% *** | 5.67 | 15.00 | 164.71% ** |
Bid-winning | / | 32.80 | / | / | 9.69 | / | |||
 12 | Third | Ambroxol hydrochloride tablets | Bid-non-winning | 2.51 | 2.48 | -1.54% *** | 4.88 | 4.61 | -5.60% *** |
Bid-winning | / | 0.34 | / | / | 8.82 | / | |||
 13 | Third | Metformin hydrochloride and glibenclamide tablets | Bid-non-winning | 1.73 | 1.45 | -16.67% *** | 36.95 | 34.53 | -6.55% ** |
Bid-winning | / | 0.10 | / | / | 59.05 | / | |||
 14 | Third | Valsartan capsules | Bid-non-winning | 6.12 | 5.32 | -13.15% *** | 13.82 | 13.04 | -5.62% *** |
Bid-winning | / | 0.25 | / | / | 25.44 | / | |||
 15 | Third | Sodium bicarbonate tablets | Bid-non-winning | 0.29 | 0.86 | 193.94% *** | 58.73 | 66.24 | 12.79% |
Bid-winning | / | 0.22 | / | / | 86.62 | / | |||
 16 | Third | Celecoxib capsules | Bid-non-winning | 8.15 | 8.05 | -1.26% *** | 8.58 | 6.81 | -20.72%*** |
Bid-winning | / | 0.59 | / | / | 16.46 | / | |||
 17 | Third | Capecitabine tablets | Bid-non-winning | 118.18 | 165.30 | 39.93% *** | 8.60 | 8.69 | 1.03% |
Bid-winning | / | 18.40 | / | / | 13.50 | / | |||
 18 | Third | Febuxostat tablets | Bid-non-winning | 19.94 | 14.70 | -26.30% *** | 10.21 | 7.08 | -30.61% |
Bid-winning | / | 1.55 | / | / | 15.08 | / | |||
 19 | Third | Domperidone tablets | Bid-non-winning | 1.41 | 1.31 | -6.87% *** | 17.99 | 14.44 | -19.76%*** |
Bid-winning | / | 0.50 | / | / | 20.68 | / | |||
 20 | Third | Ibuprofen sustained-release capsules | Bid-non-winning | 1.30 | 1.26 | -2.92% *** | 11.33 | 10.86 | -4.16%*** |
Bid-winning | / | 0.04 | / | / | 18.38 | / | |||
 21 | Third | Montelukast sodium chewable tablets | Bid-non-winning | 5.08 | 3.82 | -24.81% *** | 15.54 | 19.33 | 24.39%*** |
Bid-winning | / | 0.16 | / | / | 46.01 | / | |||
 22 | Third | Omeprazole enteric capsules | Bid-non-winning | 4.05 | 4.05 | 0.00% | 16.95 | 15.38 | -9.25%** |
Bid-winning | / | 0.23 | / | / | 23.29 | / | |||
 23 | Forth | Propofol medium and long chain fat emulsion injection | Bid-non-winning | 7.50 | 7.50 | 0.00% | 10.00 | 6.60 | -33.97% |
Bid-winning | 47.60 | 46.76 | -1.76% *** | 3.62 | 4.38 | 20.93%*** | |||
 24 | Fifth | Bicalutamide tablets | Bid-non-winning | 26.88 | 25.00 | -6.99% | 33.09 | 42.00 | 26.92% |
Bid-winning | / | 6.89 | / | / | 28.00 | / | |||
 25 | Fifth | Budesonide suspension for inhalation | Bid-non-winning | 27.79 | 24.32 | -12.46% *** | 9.49 | 11.81 | 24.37%*** |
Bid-winning | / | 6.38 | / | / | 6.25 | / | |||
 26 | Fifth | Miglitol tablets | Bid-non-winning | 5.38 | 5.38 | 0.00% | 15.02 | 24.00 | 59.80% |
Bid-winning | / | 4.00 | / | / | 21.67 | / | |||
 27 | Fifth | Ipratropium bromide solution for inhalation | Bid-non-winning | 8.74 | 8.74 | 0.00% | 7.13 | 6.28 | -11.96%*** |
Bid-winning | / | 1.94 | / | / | 4.84 | / | |||
5/32, 18.75% (bid-winning brands used in small amount before NCDP and utilization volume increased significantly after NCDP) | |||||||||
 28 | First | Flurbiprofen axetil injection | Bid-non-winning | 62.25 | 62.25 | 0.00% | 12.84 | 7.31 | -43.05%*** |
Bid-winning | 61.77 | 21.95 | -64.46% *** | 10.69 | 16.10 | 50.55%*** | |||
 29 | First | Dexmedetomidine hydrochloride injection | Bid-non-winning | 136.55 | 99.97 | -26.79% *** | 1.58 | 1.38 | -12.60%*** |
Bid-winning | 188.00 | 133.10 | -29.20% *** | 0.62 | 1.80 | 188.63%*** | |||
 30 | First | Rosuvastatin calcium tablets | Bid-non-winning | 3.25 | 3.25 | 0.00% | 22.37 | 19.52 | -12.74%*** |
Bid-winning | 1.47 | 0.16 | -89.12% *** | 57.55 | 78.46 | 36.34%** | |||
 31 | Fifth | Glipizide tablets | Bid-non-winning | 0.90 | 0.90 | 0.00% | 23.55 | 23.29 | -1.10% |
Bid-winning | 0.32 | 0.32 | 0.00% | 24.00 | 48.00 | 100.00%** | |||
 32 | Fifth | Saxagliptin tablets | Bid-non-winning | 7.97 | 7.95 | -0.19% | 17.76 | 14.00 | -21.15% |
Bid-winning | 1.66 | 1.66 | 0.00% | 30.00 | 33.00 | 10.00%** | |||
 33 | Fifth | Ropivacaine hydrochloride injection | Bid-non-winning | 68.55 | 68.55 | 0.00% | 12.84 | 7.31 | -43.05%*** |
Bid-winning | 59.46 | 13.76 | -64.46% *** | 10.69 | 16.10 | 50.55%*** | |||